Search | Clinical Trials Finder

Conditions: Smoking
Interventions: Own Brand Menthol Cigarette, Electronic Menthol Cigarette #1, Electronic Menthol Cigarette #2, Electronic Menthol Cigarette #3, Leading U.S. Nicotine Gum; Other
Lead sponsor: R.J. Reynolds Vapor Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteer
Interventions: Placebo, RO6806127; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Homocystinuria
Interventions: Pegtibatinase, Placebo; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Seizure Disorders
Interventions: Dexmedetomidine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity
Interventions: MBX 4291, Placebo; Drug
Lead sponsor: MBX Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Doral, Florida • Lexington, Kentucky • Kansas City, Missouri + 1 more

Conditions: Chronic Hepatitis D Infection
Interventions: Bulevirtide (BLV); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Edgewater, Florida • Miami, Florida • Miami Lakes, Florida + 4 more

Conditions: Recurrent Pericarditis
Interventions: VTX2735; Drug
Lead sponsor: Zomagen Biosciences Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: La Jolla, California • Orange, California • Saint Augustine, Florida + 10 more

Conditions: Hereditary Angioedema (HAE)
Interventions: CSL312; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Litchfield Park, Arizona • Scottsdale, Arizona • Orange, California + 4 more

Conditions: Healthy Volunteers, Anemia, Sickle Cell
Interventions: AG-946, AG-946 Matched Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: La Jolla, California • Boston, Massachusetts • New York, New York + 4 more

Conditions: Cystic Fibrosis
Interventions: Lumacaftor, Ivacaftor, Lumacaftor Placebo, Ivacaftor Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 38
States / cities: Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more

Conditions: Healthy
Interventions: BAF 312; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy Volunteers
Interventions: ASA, non-enteric-coated chewable aspirin; Drug
Lead sponsor: Vectura, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Springfield, Missouri

Conditions: Scleroderma, Systemic, Sclerosis, Systemic, Systemic Scleroderma, Systemic Sclerosis, Interstitial Lung Disease
Interventions: Pomalidomide (CC-4047), Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 20
States / cities: Los Angeles, California • Rancho Mirage, California • Newark, Delaware + 17 more

Conditions: Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Interventions: BAX69 Single-Route Arm, BAX69 Double-Route Arm; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Miami, Florida • Augusta, Georgia • Silver Spring, Maryland + 3 more

Conditions: Asthma, Chronic Obstructive Pulmonary Disease COPD
Interventions: AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg), AZD7594 placebo inhalation powder, AZD7594 placebo pressurized inhalation suspension; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: KT-579, Placebo; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions: Mevrometostat, Placebo, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 127
States / cities: Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 89 more

Conditions: Acute Intermittent Porphyria
Interventions: givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Birmingham, Alabama • San Francisco, California • New York, New York + 1 more

Conditions: Healthy
Interventions: ABT-436, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: SGM-1019, Placebo; Drug
Lead sponsor: Second Genome; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 10
States / cities: Chandler, Arizona • Tucson, Arizona • Panorama City, California + 7 more

Conditions: Negative Symptoms in Schizophrenia
Interventions: Roluperidone 64 mg, Olanzapine 10 MG; Drug
Lead sponsor: Minerva Neurosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Garden Grove, California • Gaithersburg, Maryland • Marlton, New Jersey

Conditions: Generalized Myasthenia Gravis
Interventions: Efgartigimod PH20 SC; Biological
Lead sponsor: argenx; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Charlotte, North Carolina • Denton, Texas • Charlottesville, Virginia

Conditions: Stable Coronary Artery Disease
Interventions: Selatogrel, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 7
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more

Search by objective public record fields.

Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Menthol Electronic Cigarettes vs Combustible Menthol Cigarettes and Nicotine Gum

A Phase 1 Study of RO6806127 in Healthy Male Volunteers

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

Dexmedetomidine in Seizure Patients

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312

Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease